Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410834 | 0.89 | HTR1A (0.30) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL6413314 | 0.88 | ERBB2 (0.31) | — | |
| SCHEMBL6406537 | 0.82 | — | — | |
| SCHEMBL6413185 | 0.81 | HTR3E (0.33) | HTR2AHTR2C | |
| SCHEMBL6406793 | 0.77 | HTR1A (0.37) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL6409305 | 0.76 | — | — | |
| SCHEMBL6406322 | 0.76 | CA2 (0.31) | — | |
| SCHEMBL6407860 | 0.67 | — | — | |
| SCHEMBL5379262 | 0.65 | HRH4 (0.32) | — | |
| SCHEMBL4576513 | 0.65 | ADRB1 (0.36) | DRD2HTR2AHTR2CDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, ADRB2, REN | HTR1A 2656/4885DRD2 982/4885DRD4 1889/4885 |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, F12, UTS2R | HTR1A 3278/4885DRD2 1020/4885DRD4 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.